remdesivir

Remdesivir is a phosphoramidate prodrug that is anabolized in cells to the active moiety, remdesivir triphosphate. It acts by inhibiting RNA-dependent RNA polymerase (RdRp). The RdRp uses remdesivir triphosphate as a substrate, leading to the incorporation of remdesivir monophosphate into the growing RNA, which then terminates chain elongation after three more nucleotides are added.

Adult

200 mg (single loading dose on day 1) followed by 100 mg once-daily maintenance doses (from day 2 onward); 5 days duration for patients not requiring mechanical ventilation; 10 days for patients not responding to initial treatment (5 additional days)

Pediatric

200 mg (single loading dose on day 1) followed by 100 mg once-daily maintenance doses (from day 2 onward) (for patients 12 years of age and older and weighing at least 40 kg)